GRAIL, Inc.GRAL财报
Nasdaq · biotechnology industry
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
主要股东
| 股东 | 持股比例 | 股数 | 变动 | 截至 |
|---|---|---|---|---|
| Illumina, Inc. | 14.50% | 4.5M | — | 2024-08-14 |
| Sessa | 9.66% | 3.0M | — | 2024-11-14 |
| PRIMECAP Management Company | 7.03% | 2.2M | — | 2024-11-12 |
| CRCM Opportunity Fund III, LP | 1.28% | 397.4K | 无变化 | 2024-09-30 |
内部人交易
Net 90d: −$15.48M · buys $0 / sells $15.48M时间范围:
类型:
身份:
| 内部人 | 身份 | 类型 | ||||
|---|---|---|---|---|---|---|
| 2026-04-15 | SUMME GREGORY L | Director | Grant | 631 | $49.79 | $31.4K |
| 2026-04-15 | CHASE WILLIAM J | Director | Grant | 408 | $49.79 | $20.3K |
| 2026-04-15 | MIZELL STEVEN | Director | Grant | 396 | $49.79 | $19.7K |
| 2026-04-08 | Aaron Freidin | Chief Financial Officer | Sell (open market) | 45.8K | $49.92 | $2.29M |
| 2026-04-08 | RAGUSA ROBERT P | Chief Executive Officer | Sell (open market) | 123.5K | $49.92 | $6.16M |
| 2026-04-08 | Ofman Joshua J. | President | Sell (open market) | 61.7K | $49.92 | $3.08M |
| 2026-03-09 | RAGUSA ROBERT P | Chief Executive Officer | Sell (open market) | 7.2K | $47.93 | $345.2K |
| 2026-03-09 | RAGUSA ROBERT P | Chief Executive Officer | Sell (open market) | 258 | $46.73 | $12.1K |
| 2026-03-09 | Aaron Freidin | Chief Financial Officer | Sell (open market) | 2.4K | $47.93 | $115.4K |
| 2026-03-09 | Aaron Freidin | Chief Financial Officer | Sell (open market) | 85 | $46.74 | $4.0K |
1–10 of 23
第 1 页 / 共 3 页